Gibson Oncology Congratulates Dr. Danzhou Yang as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University

Gibson Oncology Congratulates Dr. Danzhou Yang as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University




Gibson Oncology Congratulates Dr. Danzhou Yang as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University

MIAMI–(BUSINESS WIRE)–#cMyc–“Gibson Oncology has been honored to collaborate with Dr. Danzhou Yang and her lab for the discovery and development of novel cMyc inhibitors for a major oncogene that is believed to be over-expressed in approximately 80% of all human cancers,” stated Randall B. Riggs, President & CEO of Gibson Oncology. “Now the academic community is fully recognizing her with the appointment of Dr Yang by the Purdue Board of Trustees as a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology. “

Dr. Yang, a valued member of Gibson Oncology’s Scientific Advisory Committee, Is also the Martha and Fred Borch Endowed Chair in Cancer Therapeutics at Purdue. She is an internationally recognized leader in DNA molecular targets for cancer therapeutics, particularly DNA secondary structures known as G-quadruplexes. Dr. Yang uses NMR spectroscopy to study high-resolution molecular structures, and is regarded as an outstanding collaborator and educator. She has published 89 peer-reviewed papers in top-rated journals, and submitted seven patent applications and 22 Protein Data Bank structures. Dr Yang has lectured extensively on her research, and her laboratory program has been funded continuously by peer-reviewed NIH grants since 2000. Her service to the scientific community is also noteworthy, with membership on numerous editorial boards and leadership in scientific organizations, including the American Association for Cancer Research.

Gibson Oncology, LLC (“Gibson”), a privately-held clinical-stage company, has secured worldwide, exclusive commercial rights to a novel series of 56 rationally designed compounds called Azaindenoisoquinolines (“Aza Compounds”), from Purdue University and the National Cancer Institute. These Aza Compounds and new rationally designed compounds from Gibson’s structure activity relationship (SAR) program and in collaboration with Dr. Yang, have proven to be selective inhibitors of cMyc by binding to the G4 quadruplex in the cMyc promoter region.

Contacts

Randall B. Riggs, MBA

President & CEO

7772 Fisher Island Drive

Miami, FL 33109

rriggs@gibsononcology.com